STAAR Surgical Elevates CFO and COO As Interim Co-CEOs During Leadership Transition

STAAR Surgical Company (STAA), a leading manufacturer of advanced implantable intraocular lenses, recently named Deborah Andrews and Warren Foust as interim Co-Chief Executive Officers, effective February 1. The move follows the departure of the company’s previous chief executive in January, marking a significant shift in the organization’s leadership structure. The CFO and Chief Operating Officer are now tasked with steering the ophthalmic device maker through this transitional period.

Deborah Andrews and Warren Foust Take the Helm as Co-CEOs

The medical device company formalized the appointment of its finance chief and operations leader to the top executive positions. Deborah Andrews brings her expertise from her role as CFO, where she has managed the company’s financial strategy. Warren Foust, stepping up from his COO position, brings operational excellence to the interim co-leadership structure. This dual leadership approach allows the company to maintain continuity while undergoing its executive search process.

Comprehensive Search Underway for Permanent Executive Leadership

A search committee has been established to identify a permanent chief executive officer for STAAR Surgical. The committee is actively evaluating both internal talent and external candidates who can meet the company’s long-term strategic objectives in the competitive ophthalmic device market. This methodical approach demonstrates the company’s commitment to selecting experienced leadership qualified to navigate the evolving landscape of implantable lens technology.

Stock Performance Reflects Market Confidence

On the trading day prior to the announcement, STAA shares closed at $18.95, showing a marginal gain of 0.05% on the Nasdaq. The measured market response suggests investor confidence in the company’s interim leadership appointments and the structured approach to finding permanent executive guidance for the organization.